Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report

Papillary tumor of the pineal region (PTPR) is a rare brain tumor that probably arises from ependymal cells. There are no known systemic treatments for PTPR once it is refractory to surgery and radiation. We present the first case of a durable radiographic and clinical response of a PTPR to bevacizu...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Adam L., Salzman, Karen, Palmer, Cheryl, Jensen, Randy, Colman, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2013
Materias:
Published online: August, 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764969/
https://www.ncbi.nlm.nih.gov/pubmed/24019784
http://dx.doi.org/10.1159/000354753
_version_ 1782283215081308160
author Cohen, Adam L.
Salzman, Karen
Palmer, Cheryl
Jensen, Randy
Colman, Howard
author_facet Cohen, Adam L.
Salzman, Karen
Palmer, Cheryl
Jensen, Randy
Colman, Howard
author_sort Cohen, Adam L.
collection PubMed
description Papillary tumor of the pineal region (PTPR) is a rare brain tumor that probably arises from ependymal cells. There are no known systemic treatments for PTPR once it is refractory to surgery and radiation. We present the first case of a durable radiographic and clinical response of a PTPR to bevacizumab, an antibody against vascular endothelial growth factor, despite multiple prior treatments. Bevacizumab may be an effective treatment for PTPR.
format Online
Article
Text
id pubmed-3764969
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-37649692013-09-09 Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report Cohen, Adam L. Salzman, Karen Palmer, Cheryl Jensen, Randy Colman, Howard Case Rep Oncol Published online: August, 2013 Papillary tumor of the pineal region (PTPR) is a rare brain tumor that probably arises from ependymal cells. There are no known systemic treatments for PTPR once it is refractory to surgery and radiation. We present the first case of a durable radiographic and clinical response of a PTPR to bevacizumab, an antibody against vascular endothelial growth factor, despite multiple prior treatments. Bevacizumab may be an effective treatment for PTPR. S. Karger AG 2013-08-24 /pmc/articles/PMC3764969/ /pubmed/24019784 http://dx.doi.org/10.1159/000354753 Text en Copyright © 2013 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: August, 2013
Cohen, Adam L.
Salzman, Karen
Palmer, Cheryl
Jensen, Randy
Colman, Howard
Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report
title Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report
title_full Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report
title_fullStr Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report
title_full_unstemmed Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report
title_short Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report
title_sort bevacizumab is effective for recurrent papillary tumor of the pineal region: first report
topic Published online: August, 2013
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764969/
https://www.ncbi.nlm.nih.gov/pubmed/24019784
http://dx.doi.org/10.1159/000354753
work_keys_str_mv AT cohenadaml bevacizumabiseffectiveforrecurrentpapillarytumorofthepinealregionfirstreport
AT salzmankaren bevacizumabiseffectiveforrecurrentpapillarytumorofthepinealregionfirstreport
AT palmercheryl bevacizumabiseffectiveforrecurrentpapillarytumorofthepinealregionfirstreport
AT jensenrandy bevacizumabiseffectiveforrecurrentpapillarytumorofthepinealregionfirstreport
AT colmanhoward bevacizumabiseffectiveforrecurrentpapillarytumorofthepinealregionfirstreport

Ejemplares similares